PharmaCord to merge with Odyssey-backed Mercalis.

PharmaCord, a provider of patient services for the biopharmaceutical industry, agreed to merge with Odyssey-backed Mercalis, a life sciences commercialization company. Financial terms were not disclosed. “This combination is about more than growth — it’s about impact and transformation to meet evolving manufacturer and patient needs. By uniting PharmaCord’s deep expertise in hub services with Mercalis’s established leadership in end-to-end patient access solutions and robust infrastructure, we are building a next-generation platform that redefines how life science companies bring innovative therapies to market. Together we will unlock new efficiencies, accelerate patient access, create a seamless experience for healthcare providers and patients alike, and provide a highly compelling opportunity for employees," Robert Truckenmiller, PharmaCord CEO.